Today, San Francisco company Mahana Therapeutics announced the acquisition of Berlin-based HiDoc Technologies, operating as Cara Care.
Mahana develops digital treatments designed to empower patients with chronic conditions. The company’s initial product, Mahana IBS, was the first digital therapeutic to receive FDA clearance for the treatment of irritable bowel syndrome.
Cara Care has developed a digital therapeutic app for digestive diseases. The app covers medication management and dietary and mental health interventions to improve gastrointestinal health, and helps fill the gaps between doctor visits for gastrointestinal disease patients.
Combined, the companies address irritable bowel syndrome (IBS), Irritable bowel disorder (IBD), celiac disease, and heartburn, with a developing pipeline in tinnitus, pruritus, and vulvodynia.
Further, the acquisition of Cara Care is expected to accelerate Mahana’s market entry in Europe where the reimbursement of digital programs is outpacing the United States.
Cara Care’s IBS prescription-based digital program is currently being prescribed, and reimbursed, to thousands of patients in Germany.
According to Mahana CEO, Simon Levy:
“The transaction will accelerate our mission of reaching the millions of patients suffering from these chronic conditions including through partnerships, such as our ongoing collaboration with Bayer.
Our ability to pair our digital programs with conventional treatment options will improve overall outcomes and patient satisfaction and has the potential to greatly enhance the lifetime patient value for our consumer health and biopharmaceutical partners.”
Jim Mapes, CEO of HiDoc Technologies, said:
“Cara Care is delighted to join the Mahana team to accelerate our products' expansion within Germany and other European markets.
We see this as a great opportunity to leverage Mahana’s unique distribution and partnership model and to expand our compelling offering in Digestive Health to the US marketplace with minimal overlap.”
Financial terms of the acquisition were not disclosed.
Lead image: HiDoc Technologies. Photo: uncredited.
Would you like to write the first comment?
Login to post comments